heart failure
Conditions
Interventions
Assigned following 2 groups, when heart failure treatment is hemodynamically stable. TLV group: Add on tolvaptan (1.875mg/day to 15mg/day) with conventional diuretics for 6 months.
Conventinal diur
Sponsors
Nihon University Surugadai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Heart failure in-hospital patients with fluid retention Required continuous diuretics treatment
Exclusion criteria
Exclusion criteria: Patients with a history of hypersensitivity for tolvaptan or an analogue. Anuresis or hypernatremia. Patients who have difficulty with fluid intake or can not feel dipsesis. Pregnant woman or possibility of the pregnancy. Patients whom tolvaptan is already given at registration. Patients whom study responsibility physician judged inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in neurohormonal factors (catecholamine, renin activity, aldosterone, copeptin) | — |
Secondary
| Measure | Time frame |
|---|---|
| The finding of fluid retention, the changes in serum sodium, BUN, Cr, urinary L-FABP, dosage of diuretics, blood pressure, heart rate and 6-month prognosis (readmission and death) | — |
Countries
Japan
Contacts
Public ContactKiyoshi Iida
Nihon University Surugadai Hospital Department of Cardiology
Outcome results
None listed